This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
LatAm market rising in the eyes of pharmaceutical companies
Latin America is one of the emerging regions for the pharmaceutical industry. What are the top 5 reasons?
1. It is a fast-growing region, with fast-growing economies
According to Pharmtech, by mid-2016, the number of inhabitants in Latin America will rise to 625 million, more than six million above the estimated total population in mid-2015.
The leading countries according to VisionGain's report are Brazil, Mexico, Venezuela, Argentina, Colombia and Chile. Among the leading companies are Sanofi, EMS, Novartis, Pfizer and Bayer. Representatives from three of them are currently among our speakers.
2. Innovation, affordability and availability
Facilitation of market access is possible mainly because of the Agreement for Innovation, introduced in the second half of 2012. Companies in Latin America do a lot to work with governments and make sure innovation is available. Plus, about 78% of all medicines are paid for out-of-pocket in retail pharmacies.
3. The crisis did not have such an impact here
After the crisis, more restrictions and protectionist measures were generally imposed or enhanced, which had a negative impact for multinational companies. As pharma regulatory affairs consultant María Inés Guaia says, LatAm countries are pretty inelastic: a significant share of the pharma market is managed by national health authorities and social health insurance companies that didn't significantly cut expenditure in healthcare due to the crisis.
4. The trend towards standardized regulations is increasing
While each of the previously mentioned six major markets has adopted regulations that are based on Mercosur or PAHO recommendations, international health institutes and agencies like COFERPRIS are also pushing countries towards authorizations, certification and better consistency across countries.
5. Clinical trials and R&D
Currently, an estimated 4,000 clinical trials are being conducted. Discover the future of compliance in this rising market.
Be part of the event!
2nd Annual Pharmaceutical Compliance in Latin America Congress
Interested in this topic?
Project & Portfolio Management for Pharma and Biotech – EAST
For the upcoming Project and Portfolio Management for Pharma and Biotech Conference, Fleming presents a high-level meeting building on more than a decade of experience in running global Pharma PPM events worldwide.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?
With improved patient engagement to increased patient adherence
Chronic illnesses are commonly treated with the long-term use of medications. This treatment could be successful, however, its benefits are overshadowed by the fact that 50% of patients don't take their medications as prescribed. Reveal all the alarming numbers of non-adherence and learn how to decrease it with improved patient engagement.